2026-06-30T02:01:14Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/51132024-10-31T11:42:14Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605
Repisalud
author
Dondo, Tatendashe B.
author
Hall, Marlous
author
West, Robert M.
author
Jernberg, Tomas
author
Lindahl, Bertil
author
Bueno, Hector
author
Danchin, Nicolas
author
Deanfield, John E.
author
Hemingway, Harry
author
Fox, Keith A. A.
author
Timmis, Adam D.
author
Gale, Chris P.
funder
British Health Foundation
funder
National Institute for Health Research (Reino Unido)
funder
Medical Research Council (Reino Unido)
2017-10-20T10:23:11Z
2017-10-20T10:23:11Z
2017
J Am Coll Cardiol. 2017; 69(22):2710-2720
10.1016/j.jacc.2017.03.578
1558-3597
0735-1097
Journal of the American College of Cardiology
28571635
http://hdl.handle.net/20.500.12105/5113
BACKGROUND For acute myocardial infarction (AMI) without heart failure (HF), it is unclear if beta-blockers are associated with reduced mortality. OBJECTIVES The goal of this study was to determine the association between beta-blocker use and mortality in patients with AMI without HF or left ventricular systolic dysfunction (LVSD). METHODS This cohort study used national English and Welsh registry data from the Myocardial Ischaemia National Audit Project. A total of 179,810 survivors of hospitalization with AMI without HF or LVSD, between January 1, 2007, and June 30, 2013 (final follow-up: December 31, 2013), were assessed. Survival-time inverse probability weighting propensity scores and instrumental variable analyses were used to investigate the association between the use of beta-blockers and 1-year mortality. RESULTS Of 91,895 patients with ST-segment elevation myocardial infarction and 87,915 patients with non-ST-segment elevation myocardial infarction, 88,542 (96.4\%) and 81,933 (93.2\%) received beta-blockers, respectively. For the entire cohort, with> 163,772 person-years of observation, there were 9,373 deaths (5.2\%). Unadjusted 1-year mortality was lower for patients who received beta-blockers compared with those who did not (4.9\% vs. 11.2\%; p < 0.001). However, after weighting and adjustment, there was no significant difference in mortality between those with and without beta-blocker use (average treatment effect [ATE] coefficient: 0.07; 95\% confidence interval [CI]: -0.60 to 0.75; p = 0.827). Findings were similar for ST-segment elevation myocardial infarction (ATE coefficient: 0.30; 95\% CI: -0.98 to 1.58; p = 0.637) and non-ST-segment elevation myocardial infarction (ATE coefficient: -0.07; 95\% CI: -0.68 to 0.54; p = 0.819). CONCLUSIONS Among survivors of hospitalization with AMI who did not have HF or LVSD as recorded in the hospital, the use of beta-blockers was not associated with a lower risk of death at any time point up to 1 year. (beta-Blocker Use and Mortality in Hospital Survivors of Acute Myocardial Infarction Without Heart Failure; (C) 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
eng
average treatment effect
NSTEMI
Preserved left ventricular systolic function
Propensity score
STEMI
Survival
DISEASE
TRIAL
INTERVENTION
GUIDELINES
METOPROLOL
MANAGEMENT
ELEVATION
OUTCOMES
THERAPY
Beta-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction
journal article
URL
https://repisalud.isciii.es/bitstreams/42d074b5-222b-4585-b45b-e6b8e178195d/download
File
MD5
303bc3e31b95dacfd8c19f833b0d0815
1363056
application/pdf
β-BlockersAndMortalityAfterAcute_2017
URL
https://repisalud.isciii.es/bitstreams/f7800686-d16b-47e5-b8a5-94cf210b6c96/download
File
MD5
26ddce4609e22c3a0745582ff5501c34
2129452
application/vnd.openxmlformats-officedocument.wordprocessingml.document
β-BlockersAndMortalityAfterAcute_2017_Supp
URL
https://repisalud.isciii.es/bitstreams/835a3436-7aa7-4465-8dcb-b4960c6adaff/download
File
MD5
24c688f775077414baf598c7c7d08309
45855
text/plain
β-BlockersAndMortalityAfterAcute_2017.txt
URL
https://repisalud.isciii.es/bitstreams/ce3d3d12-7480-481e-a2e0-21a310f5311e/download
File
MD5
46fa41ce28d941dc7a50b65443487bdb
45731
text/plain
β-BlockersAndMortalityAfterAcute_2017.txt
URL
https://repisalud.isciii.es/bitstreams/a24cb192-0fb5-4447-b572-87b07ffe0d4e/download
File
MD5
57add2517476a619561338d4aea85fc8
54307
text/plain
β-BlockersAndMortalityAfterAcute_2017_Supp.txt